Experimental treatments
for hypoparathyroidism

Overview

While progress has been made in the treatment of hypoparathyroidism in recent years, several experimental therapies are undergoing clinical testing. Major approaches include replacing the deficient parathyroid hormone and using targeted drugs to reduce the activity of overactive calcium-sensing receptors.

Eneboparatide

Eneboparatide is an experimental treatment that mimics the action of the PTH hormone to normalize calcium levels and ease hypoparathyroidism symptoms.

Learn more

Encaleret

Encaleret is an experimental small molecule therapy for autosomal dominant hypocalcemia type 1, a rare type of hypoparathyroidism, as well as chronic hypoparathyroidism. It is intended to help restore calcium to normal levels in the blood and urine, and is undergoing clinical trials.

Learn more

MBX 2019

MBX 2019 is an experimental treatment intended to provide the body with a long-acting form of the PTH hormone for people with chronic hypoparathyroidism. It is being tested as a once-weekly, under-the-skin, injection.

Learn more